List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 916 studies with search of: melanoma
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Trial for the Evaluation of the Effect of Systemic Low-Dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-in-Adjuvant, in Patients With High Risk Melanoma
Condition: Melanoma
Interventions: Drug: low-dose IL-2;   Biological: melanoma vaccine
2 Completed MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 Melanoma Peptide Vaccine
3 Completed Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine
4 Active, not recruiting Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: incomplete Freund's adjuvant;   Biological: peptide 946 melanoma vaccine;   Biological: peptide 946-tetanus peptide conjugate melanoma vaccine;   Biological: tetanus peptide melanoma vaccine
5 Completed Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Condition: Melanoma
Intervention: Biological: Class 4 and Class 12 melanoma peptide vaccines
6 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
7 Recruiting Melanoma Risk-Reduction Among Patients and Family Members
Condition: Melanoma
Interventions: Behavioral: Questionnaire;   Behavioral: Interview
8 Recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
9 Active, not recruiting Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Drug: cyclophosphamide
10 Completed Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Intervention: Biological: recombinant interferon beta
11 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
12 Recruiting Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
13 Recruiting A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Condition: Melanoma
Interventions: Biological: HyperAcute vaccine;   Drug: Pegylated Interferon-Alpha 2b
14 Active, not recruiting Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim
15 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim
16 Suspended M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
17 Recruiting Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
18 Completed Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
Condition: Melanoma
Interventions: Genetic: Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes;   Biological: Intranodal booster immunizations with synthetic melanoma associated epitopes
19 Active, not recruiting Melanoma Vaccine With Peptides and Leuprolide
Condition: Melanoma
Interventions: Drug: Leuprolide;   Biological: GP100: 209-217(210M) Peptide;   Biological: MAGE-3 Peptide
20 Active, not recruiting Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine;   Biological: tyrosinase peptide

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services